LM-302 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction.

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase III for Marginal Zone B-cell Lymphoma.

Odronextamab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

FP-045 is under clinical development by Foresee Pharmaceuticals and currently in Phase II for Fanconi Anemia. According to GlobalData, Phase II drugs for Fanconi Anemia does not have sufficient ...

Satralizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase III for Demyelinating Diseases.

Vemurafenib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Thyroid Cancer.